Coagulation Profile and Outcomes of COVID-19 Patients at Wahidin Sudirohusodo Hospital, Makassar, Indonesia

Authors

  • Soraya Wildhani Jamil Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
  • Muhammad Ilyas Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia image/svg+xml
  • Nur Ahmad Department of Internal Medicine, Division of Pulmonology and Respiratory, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia image/svg+xml
  • Syakib Bakri Department of Internal Medicine, Division of Nephrology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia image/svg+xml
  • Tutik Hardjianti Department of Internal Medicine, Division of Hematology Oncology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia image/svg+xml
  • Muhammad Lutfi Parewangi Department of Internal Medicine, Division of Gastroentero Hepatology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia image/svg+xml https://orcid.org/0000-0001-9257-9344
  • Arifin Seweng Department of Biostatistics, Public Health Faculty, Hasanuddin University, Makassar, Indonesia image/svg+xml

DOI:

https://doi.org/10.3889/oamjms.2022.9109

Keywords:

COVID-19, Coagulation, Prothrombin time, Outcome, Platelet

Abstract

Background: Coronavirus disease 2019 (COVID-19) is a viral pneumonia infection that spreads rapidly globally (with a number of cases > 15,000,000 worldwide and mortality of ±4%) until it is designated a pandemic by the World Health Organization (WHO). One of the complications of COVID-19 is the incidence of coagulopathy and thromboembolism. The coronavirus, SARS-CoV-2, activates inflammatory and thrombotic processes. Coagulopathy and abnormal coagulation parameters are indicated among the most significant biomarkers of poor prognosis in COVID-19 patients. COVID-19-associated coagulopathy is characterized by a decreased platelet count and the presence of a cytokine storm indicating an extreme hypercoagulable state. This study aims to determine the coagulation profile of moderate-severe patients and outcomes in COVID-19 patients

Methods: The study was conducted in a hospital in Makassar: Infection Center RS. Wahidin Sudirohusodo. Medical Record Data for all inpatients who have been diagnosed with COVID-19 through the RT-PCR test taken from January 2021-August 2021.Statistical tests in the form of the Kolmogorov-Smirnov test to assess the Normality of the Data, Chi-Square test, and the calculation of the out ratio (OR) Mann-Whitney test, Independent T-Test. Multivariate analysis was carried out using a Multiple Logistic Regression-Backward Wald Method. The results of the statistical test were significant if the p-value <0.05.

 

Results:

The research subjects were 231 patients with confirmed COVID-19. The mean PT, D-Dimer, and Fibrinogen were higher in severe COVID-19 than moderate COVID-19 and had significant results. While PLT did not have significant results against moderate-severe COVID-19. The relationship between groups of coagulation marker variables was found to have a significant relationship with moderate to severe COVID-19. 4.     All coagulation markers were significantly related to the outcome (p<0.05). The mean value of each variable was found to be greater in patients with outcomes who died

 

Conclusion:

There was an increase in all coagulation markers in moderate to severe COVID-19 except for PLT which was not significant. All coagulation markers are significantly related to outcome

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): Current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951. https://doi.org/10.1016/j.ijantimicag.2020.105951 PMid:32234466 DOI: https://doi.org/10.1016/j.ijantimicag.2020.105951

Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chinese Med Assoc. 2020;83(3):217-20. https://doi.org/10.1097/JCMA.0000000000000270 PMid:32134861 DOI: https://doi.org/10.1097/JCMA.0000000000000270

Oley MH, Oley MC, Kepel BJ, Tjandra DE, Langi FL, Herwen, et al. ICAM-1 levels in patients with covid-19 with diabetic foot ulcers: A prospective study in Southeast Asia. Ann Med Surg (Lond). 2021;63:102171. https://doi.org/10.1016/j.amsu.2021.02.017 PMid:33585030 DOI: https://doi.org/10.1016/j.amsu.2021.02.017

Djalante R, Lassa J, Setiamarga D, Sudjatma A, Indrawan M, Haryanto B, et al. Review and analysis of current responses to COVID-19 in Indonesia: Period of January to March 2020. Prog Disaster Sci. 2020;6:100091. https://doi.org/10.1016/j.pdisas.2020.100091 PMid:34171011 DOI: https://doi.org/10.1016/j.pdisas.2020.100091

Tsai PH, Lai WY, Lin YY, Luo YH, Lin YT, Chen HK, et al. Clinical manifestation and disease progression in COVID-19 infection. J Chinese Med Assoc. 2021;84(1):3-8. https://doi.org/10.1097/JCMA.0000000000000463 PMid:33230062 DOI: https://doi.org/10.1097/JCMA.0000000000000463

Da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, De Oliveira TF, Campos Alcântara R, Monteiro Arnozo G, et al. Clinical manifestations of COVID-19 in the general population: Systematic review. Wien Klin Wochenschr. 2021;133(7-8):377-82. https://doi.org/10.1007/s00508-020-01760-4 PMid:33242148 DOI: https://doi.org/10.1007/s00508-020-01760-4

Mehta OP, Bhandari P, Raut A, Kacimi SE, Huy NT. Coronavirus disease (COVID-19): Comprehensive review of clinical presentation. Front Public Health. 2021;8:582932. https://doi.org/10.3389/fpubh.2020.582932 PMid:33520910 DOI: https://doi.org/10.3389/fpubh.2020.582932

Köse N, Yıldırım T, Akın F, Yıldırım SE, Altun I. Prognostic role of NLR, PLR, and LMR in patients with pulmonary embolism. Bosn J Basic Med Sci. 2020;20(2):248-53. https://doi.org/10.17305/bjbms.2019.4445 PMid:31724521 DOI: https://doi.org/10.17305/bjbms.2019.4445

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43. https://doi.org/10.1001/jamainternmed.2020.0994 PMid:32167524 DOI: https://doi.org/10.1001/jamainternmed.2020.0994

Araya S, Mamo MA, Tsegay YG, Atlaw A, Aytenew A, Hordofa A, et al. Blood coagulation parameter abnormalities in hospitalized patients with confirmed COVID-19 in Ethiopia. PLoS One. 2021;16(6):0252939. https://doi.org/10.1371/journal.pone.0252939 PMid:34153056 DOI: https://doi.org/10.1371/journal.pone.0252939

Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7. https://doi.org/10.1111/jth.14768 PMid:32073213 DOI: https://doi.org/10.1111/jth.14768

Mehrdad R, Zahra K, Mansouritorghabeh H. Hemostatic system (Fibrinogen Level, D-Dimer, and FDP) in severe and non-severe patients with COVID-19: A systematic review and meta-analysis. Clin Appl Thromb Hemost. 2021;27:1-13. https://doi.org/10.1177/10760296211010973 PMid:34933579 DOI: https://doi.org/10.1177/10760296211010973

Long H, Nie L, Xiang X, Li H, ZHANG X, Fu X, et al. D-Dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis. Biomed Res Int. 2020;2020:6159720. https://doi.org/10.1155/2020/6159720 PMid:32596339 DOI: https://doi.org/10.1155/2020/6159720

Goswami J, MacArthur TA, Sridharan M, Pruthi RK, McBane RD, Witzig TE, et al. A review of pathophysiology, clinical features, and management options of COVID-19 associated coagulopathy. Shock. 2021;55(6):700-16. https://doi.org/10.1097/SHK.0000000000001680 PMid:33378321 DOI: https://doi.org/10.1097/SHK.0000000000001680

Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 2021;88(1):15-27. https://doi.org/10.1159/000512007 PMid:33049751 DOI: https://doi.org/10.1159/000512007

Sayad B, Rahimi Z. Blood coagulation parameters in patients with severe COVID-19 from Kermanshah province, islamic republic of Iran. East Mediterr Health J. 2020;26(9):999-1004. https://doi.org/10.26719/emhj.20.105 PMid:33047789 DOI: https://doi.org/10.26719/emhj.20.105

Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. J Intensive Care. 2020;8:49. https://doi.org/10.1186/s40560-020-00466-z PMid:32665858 DOI: https://doi.org/10.1186/s40560-020-00466-z

Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, Bajracharya T, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One. 2021;16(8):0256744. https://doi.org/10.1371/journal.pone.0256744 PMid:34437642 DOI: https://doi.org/10.1371/journal.pone.0256744

Zhan H, Chen H, Liu C, Cheng L, Yan S, Li H, et al. Diagnostic value of D-dimer in COVID-19: A meta-analysis and meta-regression. Clin Appl Thromb Hemost. 2021;27:1-10. https://doi.org/10.1177/10760296211010976 PMid:33926262 DOI: https://doi.org/10.1177/10760296211010976

Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res. 2020;194:101-15. https://doi.org/10.1016/j.thromres.2020.06.029 PMid:32788101 DOI: https://doi.org/10.1016/j.thromres.2020.06.029

Gómez-Mesa JE, Galindo-Coral S, Montes MC, Muñoz Martin AJ. Thrombosis and coagulopathy in COVID-19. Curr Probl Cardiol. 2021;46(3):100742. https://doi.org/10.1016/j.cpcardiol.2020.100742 PMid:33243440 DOI: https://doi.org/10.1016/j.cpcardiol.2020.100742

Di Micco P, Russo V, Carannante N, Imparato M, Cardillo G, Lodigiani C. Prognostic value of fibrinogen among COVID-19 patients admitted to an emergency department: An Italian cohort study. J Clin Med. 2020;9(12):4134. https://doi.org/10.3390/jcm9124134 PMid:33371524 DOI: https://doi.org/10.3390/jcm9124134

Long W, Yang J, Li Z, Li J, Chen S, Chen D, et al. Abnormal fibrinogen level as a prognostic indicator in coronavirus disease patients: A retrospective cohort study. Front Med (Lausanne). 2021;8:687220. https://doi.org/10.3389/fmed.2021.687220 PMid:34195213 DOI: https://doi.org/10.3389/fmed.2021.687220

Eljilany I, Elzouki AN. D-dimer, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: A narrative review. Vasc Health Risk Manag. 2020;16:455-62. https://doi.org/10.2147/VHRM.S280962 PMid:33223833 DOI: https://doi.org/10.2147/VHRM.S280962

Zhang A, Leng Y, Zhang Y, Wu K, Ji Y, Lei S, et al. Meta-analysis of coagulation parameters associated with disease severity and poor prognosis of COVID-19. Int J Infect Dis. 2020;100:441-8. https://doi.org/10.1016/j.ijid.2020.09.021 PMid:32947052 DOI: https://doi.org/10.1016/j.ijid.2020.09.021

Xu W, Fei L, Huang CL, Li WX, Xie XD, Li Q, et al. Dynamic changes in coagulation parameters and correlation with disease severity and mortality in patients with COVID-19. Aging (Albany NY). 2021;13(10):13393-404. https://doi.org/10.18632/aging.203052 PMid:34031269 DOI: https://doi.org/10.18632/aging.203052

Zou Y, Guo H, Zhang Y, Zhang Z, Liu Y, Wang J, et al. Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. Biosci Trends. 2020;14(4):285-9. https://doi.org/10.5582/bst.2020.03086 PMid:32350161 DOI: https://doi.org/10.5582/bst.2020.03086

Downloads

Published

2022-04-12

How to Cite

1.
Jamil SW, Ilyas M, Ahmad N, Bakri S, Hardjianti T, Parewangi ML, Seweng A. Coagulation Profile and Outcomes of COVID-19 Patients at Wahidin Sudirohusodo Hospital, Makassar, Indonesia. Open Access Maced J Med Sci [Internet]. 2022 Apr. 12 [cited 2024 Mar. 28];10(B):1097-101. Available from: https://oamjms.eu/index.php/mjms/article/view/9109

Issue

Section

Infective Diseases

Categories

Most read articles by the same author(s)